Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?

Author:
Tianhong Li
Search for other papers by Tianhong Li in
Current site
Google Scholar
PubMedClose
 MD, PhD
Volume/Issue:
Volume 18: Issue 1
Online Publication Date:
Jan 2020
DOI:
https://doi.org/10.6004/jnccn.2019.7523
Restricted access

Disclosure: Dr. Li has disclosed that she is a scientific advisor for Foundation Medicine and ArcherDx, Inc., and receives grant/research support from Pfizer, LabyRx Immunologic Therapeutics Limited, Hengrui, and Merck.

Correspondence: Tianhong Li, MD, PhD, University of California Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817. Email: thli@ucdavis.edu

View associated content

  • Collapse
  • Expand
  • 1.

    Schwaederle M, Zhao M, Lee JJ, et al.. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol 2016;2:1452–1459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Chakiba C, Grellety T, Bellera C, Italiano A. Encouraging trends in modern phase 1 oncology trials. N Engl J Med 2018;378:2242–2243.

  • 3.

    Gandara DR, Li T, Lara PN Jr, et al.. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer 2012;13:321–325.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Diabetes Patient Advocacy Coalition. How the FDA drug approval process works. Available at: https://diabetespac.org/fda-drug-approval-process/. Accessed December 1, 2019.

  • 5.

    Selaru P, Tang Y, Huang B, et al.. Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib. Clin Transl Sci 2016;9:63–73.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Kang SP, Gergich K, Lubiniecki GM, et al.. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol 2017;28:1388–1398.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    FDA approves Vitrakvi (larotrectinib), the first ever TRK inhibitor, for patients with advanced solid tumors harboring an NTRK gene fusion. Available at: https://www.prnewswire.com/news-releases/fda-approves-vitrakvi-larotrectinib-the-first-ever-trk-inhibitor-for-patients-with-advanced-solid-tumors-harboring-an-ntrk-gene-fusion1-2-300755551.html. Accessed December 1, 2019.

  • 8.

    Gyawali B, D’Andrea E, Franklin JM, Kesselheim AS. Response rates and durations of response for biomarker-based cancer drugs in non-randomized versus randomized trials. J Natl Compr Canc Netw 2020;18:36–43.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: https://www.fda.gov/drugs/scienceresearch/ucm572698.htm. Accessed December 9, 2019.

  • 10.

    Osgood C, Mulkey F, Mishra-Kalyani PS, et al.. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 9508.

    • Crossref
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Page Numbers:
2
Article Category:
Other
Print Publication Date:
01 Jan 2020
Online Publication Date:
Jan 2020
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1616 108 9
PDF Downloads 498 86 7
EPUB Downloads 0 0 0